SANUWAVE Updates on FDA Review of dermaPACE Premarket Approval Application

SANUWAVE Health, Inc. (OTCBB: SNWV) , an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, today reported it has received a major deficiency letter from the United States Food and Drug Administration (FDA) regarding the FDA's review of the dermaPACE ® Premarket Approval Application (PMA) for the treatment of diabetic foot ulcers. The FDA issues a major deficiency lett...continued SNWV

URL: http://www.investorpoint.com/news/OTCBULLB/47065643/